The Relevance of Insulin Action in the Dopaminergic System
- PMID: 31474827
- PMCID: PMC6706784
- DOI: 10.3389/fnins.2019.00868
The Relevance of Insulin Action in the Dopaminergic System
Abstract
The advances in medicine, together with lifestyle modifications, led to a rising life expectancy. Unfortunately, however, aging is accompanied by an alarming boost of age-associated chronic pathologies, including neurodegenerative and metabolic diseases. Interestingly, a non-negligible interplay between alterations of glucose homeostasis and brain dysfunction has clearly emerged. In particular, epidemiological studies have pointed out a possible association between Type 2 Diabetes (T2D) and Parkinson's Disease (PD). Insulin resistance, one of the major hallmark for etiology of T2D, has a detrimental influence on PD, negatively affecting PD phenotype, accelerating its progression and worsening cognitive impairment. This review aims to provide an exhaustive analysis of the most recent evidences supporting the key role of insulin resistance in PD pathogenesis. It will focus on the relevance of insulin in the brain, working as pro-survival neurotrophic factor and as a master regulator of neuronal mitochondrial function and oxidative stress. Insulin action as a modulator of dopamine signaling and of alpha-synuclein degradation will be described in details, too. The intriguing idea that shared deregulated pathogenic pathways represent a link between PD and insulin resistance has clinical and therapeutic implications. Thus, ongoing studies about the promising healing potential of common antidiabetic drugs such as metformin, exenatide, DPP IV inhibitors, thiazolidinediones and bromocriptine, will be summarized and the rationale for their use to decelerate neurodegeneration will be critically assessed.
Keywords: Parkinson’s disease; dopamine; insulin resistance; neurodegeneration; type 2 diabetes mellitus.
Figures
Similar articles
-
Diabetes Mellitus and Parkinson's Disease: Shared Pathophysiological Links and Possible Therapeutic Implications.Cureus. 2020 Aug 18;12(8):e9853. doi: 10.7759/cureus.9853. Cureus. 2020. PMID: 32832307 Free PMC article. Review.
-
Mitochondrial biogenesis: pharmacological approaches.Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118. Curr Pharm Des. 2014. PMID: 24606795
-
Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.Eur J Med Chem. 2019 May 1;169:185-199. doi: 10.1016/j.ejmech.2019.03.009. Epub 2019 Mar 8. Eur J Med Chem. 2019. PMID: 30877973 Review.
-
Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice.Exp Neurol. 2014 Jan;251:22-9. doi: 10.1016/j.expneurol.2013.11.001. Epub 2013 Nov 9. Exp Neurol. 2014. PMID: 24220636
-
Parkinson's disease and diabetes mellitus: common mechanisms and treatment repurposing.Neural Regen Res. 2022 Aug;17(8):1652-1658. doi: 10.4103/1673-5374.332122. Neural Regen Res. 2022. PMID: 35017411 Free PMC article. Review.
Cited by
-
Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):858-869. doi: 10.1021/acsptsci.1c00013. eCollection 2021 Apr 9. ACS Pharmacol Transl Sci. 2021. PMID: 33860208 Free PMC article.
-
MicroRNA-Targeted Gene Regulation in Salivary Gland Tissue of De Novo Parkinson's Disease Patients.Mol Neurobiol. 2024 Oct 29. doi: 10.1007/s12035-024-04581-y. Online ahead of print. Mol Neurobiol. 2024. PMID: 39467986
-
Diabetes Mellitus and Parkinson's Disease: Shared Pathophysiological Links and Possible Therapeutic Implications.Cureus. 2020 Aug 18;12(8):e9853. doi: 10.7759/cureus.9853. Cureus. 2020. PMID: 32832307 Free PMC article. Review.
-
Auditory mismatch responses are differentially sensitive to changes in muscarinic acetylcholine versus dopamine receptor function.Elife. 2022 May 3;11:e74835. doi: 10.7554/eLife.74835. Elife. 2022. PMID: 35502897 Free PMC article. Clinical Trial.
-
Potential Crosstalk Between Parkinson's Disease and Energy Metabolism.Aging Dis. 2021 Dec 1;12(8):2003-2015. doi: 10.14336/AD.2021.0422. eCollection 2021 Dec. Aging Dis. 2021. PMID: 34881082 Free PMC article. Review.
References
-
- Aime P., Hegoburu C., Jaillard T., Degletagne C., Garcia S., Messaoudi B., et al. (2012). A physiological increase of insulin in the olfactory bulb decreases detection of a learned aversive odor and abolishes food odor-induced sniffing behavior in rats. PLoS One 7:e51227. 10.1371/journal.pone.0051227 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources